Applications of Metamizole Sodium in Industrial Manufacturing

Metamizole Sodium serves as a critical pharmaceutical intermediate and functional ingredient across several tightly regulated industrial sectors. We manufacture to ensure reliable integration into downstream processes, maintaining traceability and strict adherence to international standards. Below, we detail the principal application pathways based on verified industry practice.

1. Pharmaceutical Finished Dosage Production (Analgesic and Antipyretic Tablets)

Global pharmaceutical formulators use Metamizole Sodium extensively in the production of prescription and over-the-counter tablets for pain and fever management. Facilities must implement validated blending, granulation, and tablet compression protocols. Compliance with pharmacopoeial assay and impurity controls is mandatory to prevent cross-contamination and guarantee the safety profile for end patients. During scale-up, manufacturers calibrate particle size and bulk density for direct compression or wet granulation lines, ensuring consistent dissolution and bioavailability in the final product.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) Monograph 01/2008:1234
• United States Pharmacopeia (USP) General Chapter <795> and <795> Compounding Regulations
• Good Manufacturing Practice (GMP) for Finished Pharmaceuticals (ICH Q7)
• Health Canada Food and Drug Act—Schedule F

Typical usage ratio

• 250 mg to 1000 mg per tablet, adjusted based on therapeutic target and formulation requirements
• The active ingredient typically comprises 25%–80% of tablet core mass depending on formulation size
• Filler and excipient ratios modified depending on dissolution test results

Downstream process integration

• Direct addition into API blending or granulation step post-quality release
• Integration into tableting lines after material dispensation and identification
• Sampling for HPLC potency and impurity testing before final compression

Final product types

• Analgesic and antipyretic Rx tablets
• OTC pain relief multipacks
• Branded and generic metered-dose tablets for pharmacy supply

2. Injectable Analgesic Solution Manufacturing

Sterile production lines in human and veterinary medicine utilize this compound for parenteral pain management. Operations require stringent pyrogen and endotoxin monitoring during solution formulation, followed by in-process sterile filtration, vial filling, and terminal sterilization. Water-for-injection serves as the primary solvent, making control of raw material microbial content essential to final batch release. Manufacturers must maintain detailed batch records to support pharmacovigilance and traceability obligations.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) 2.9.5 Sterility Test
• USP <71> Sterility and <85> Bacterial Endotoxin Test
• GMP Annex 1: Manufacture of Sterile Medicinal Products
• Veterinary Medicines Directorate (VMD) UK—Sterile Preparation Guidelines

Typical usage ratio

• 10%–50% w/v in final injectable solution (100 mg to 500 mg per mL)
• Concentration adjusted for single-dose vs. multi-dose vial formats
• Buffer and stabilizer levels set per pH and osmolarity requirements

Downstream process integration

• Dissolution with WFI in jacketed mixing vessels
• Inline filtration (0.22 micron) upstream of aseptic filling
• Filling into glass ampoules or rubber-stoppered vials under Class A laminar flow
• Batch released upon passing sterility and endotoxin clearance

Final product types

• Sterile injectable ampoules for human hospitals
• Multi-dose veterinary injection vials
• Pre-filled syringe kits for clinical use

3. Bulk API Export for Global Pharmaceutical Formulation

Downstream pharmaceutical manufacturing partners worldwide import bulk-grade Metamizole Sodium as an active pharmaceutical ingredient. Bulk export requires validated API packaging, moisture barrier performance, and international shipping documentation. Quality control includes full COA (certificate of analysis) batch release and compliance with destination market registration dossiers, including DMF (Drug Master File) submission. Consistent particle characteristics and impurity limits must match customer’s formulation specs.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Certificate of Suitability (CEP, EDQM) for Europe
• WHO Good Distribution Practices (GDP)
• China DMF (Drug Master File) and EU EudraGMDP listing

Typical usage ratio

• Exported in lots of 25 kg, 50 kg, or 200 kg based on customer batch runs
• Tonnage calculated according to annual formulation batch size planning

Downstream process integration

• Bulk transfer into customer blending and dosage-form manufacturing tanks
• Sampling and analytical confirmation before formulation stage
• Controlled temperature storage at 15–25°C until use

Final product types

• Pharmaceutical grade APIs for tableting, capsules, and injectable lines
• Registered APIs for regulated market entry
• Intermediate APIs for licensed local formulation

4. Veterinary Formulation Ingredient (Oral Drench and Bolus Manufacturing)

Formulators in the animal health industry use Metamizole Sodium to produce oral pain-relief drenches and bolus forms, especially for livestock applications. The compound is incorporated during wet granulation or suspension blending phases, with well-defined particle size distribution to prevent settling or segregation. Veterinary end products require residue trial data, withdrawal period documentation, and post-formulation stability validation before commercial release.

Industry compliance standards

• VICH GL10 (Good Clinical Practice) for Veterinary Medicinal Products
• Australian Pesticides and Veterinary Medicines Authority (APVMA) Guidelines
• CVMP Guidelines for Residue Testing (European Medicines Agency)
• GMP for Veterinary Medicinals (EU Regulation 2019/6)

Typical usage ratio

• 10%–30% w/w in oral drench formulation
• 100 mg to 2000 mg per bolus, tailored to livestock body weight
• Suspending and wetting agents dosed according to animal species and application volume

Downstream process integration

• Dispensed into aqueous or oil suspension blending units
• Wet granulated and compressed for bolus production, with in-process sampling
• Homogeneity testing and stability sampling before packaging

Final product types

• Oral drench pain-relief solutions for cattle and equines
• Boluses for livestock
• Blended veterinary powders for in-feed administration